WHO IMPLEMENTATION TOOL FOR PRE-EXPOSURE PROPHYLAXIS (PrEP) OF HIV INFECTION CLINICAL

Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children: recommendations for

Guidance on Pre-exposure oral prophylaxis (PrEP) for serodiscordant couples, men who have sex with men and transgender women at high risk of HIV in..

Effective PrEP use is different from adherence to HIV treatment in that PrEP can be started and stopped as a person moves through “seasons of risk”, whereas treatment is

High incidence and prevalence of sexually transmitted infections (STIs) in HIV pre-exposure prophylaxis (PrEP) users: systematic review and analysis.. (Manuscript

All people at substantial risk of HIV infection who could be eligible for PrEP should be offered HIV testing services. Prior to starting or restarting PrEP, it is critical to rule

This systematic review and meta-analysis sought to evaluate the evidence for use of oral PrEP as an additional prevention choice for HIV prevention across populations regarding

Following US Food and Drugs Administration approval in July 2012 of daily oral tenofovir and emtricitabine for pre-exposure prophylaxis (PrEP) to prevent HIV infection in

Uninfected pregnant or breastfeeding women in high incidence areas have also been suggested as a potential target population for PrEP, but infants exposed to HIV through breast